These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 19671750)

  • 1. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
    Leow CC; Chesebrough J; Coffman KT; Fazenbaker CA; Gooya J; Weng D; Coats S; Jackson D; Jallal B; Chang Y
    Mol Cancer Ther; 2009 Aug; 8(8):2131-41. PubMed ID: 19671750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.
    Scaltriti M; Serra V; Normant E; Guzman M; Rodriguez O; Lim AR; Slocum KL; West KA; Rodriguez V; Prudkin L; Jimenez J; Aura C; Baselga J
    Mol Cancer Ther; 2011 May; 10(5):817-24. PubMed ID: 21383049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
    Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
    Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
    Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
    Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
    Konecny GE; Pegram MD; Venkatesan N; Finn R; Yang G; Rahmeh M; Untch M; Rusnak DW; Spehar G; Mullin RJ; Keith BR; Gilmer TM; Berger M; Podratz KC; Slamon DJ
    Cancer Res; 2006 Feb; 66(3):1630-9. PubMed ID: 16452222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
    Garrett JT; Sutton CR; Kuba MG; Cook RS; Arteaga CL
    Clin Cancer Res; 2013 Feb; 19(3):610-9. PubMed ID: 23224399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.
    Scaltriti M; Verma C; Guzman M; Jimenez J; Parra JL; Pedersen K; Smith DJ; Landolfi S; Ramon y Cajal S; Arribas J; Baselga J
    Oncogene; 2009 Feb; 28(6):803-14. PubMed ID: 19060928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
    Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
    García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
    Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.
    Floris G; Debiec-Rychter M; Wozniak A; Stefan C; Normant E; Faa G; Machiels K; Vanleeuw U; Sciot R; Schöffski P
    Mol Cancer Ther; 2011 Oct; 10(10):1897-908. PubMed ID: 21825009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
    Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
    Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
    O'Donovan N; Byrne AT; O'Connor AE; McGee S; Gallagher WM; Crown J
    Invest New Drugs; 2011 Oct; 29(5):752-9. PubMed ID: 20229355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
    Dave B; Migliaccio I; Gutierrez MC; Wu MF; Chamness GC; Wong H; Narasanna A; Chakrabarty A; Hilsenbeck SG; Huang J; Rimawi M; Schiff R; Arteaga C; Osborne CK; Chang JC
    J Clin Oncol; 2011 Jan; 29(2):166-73. PubMed ID: 21135276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
    Wang YC; Morrison G; Gillihan R; Guo J; Ward RM; Fu X; Botero MF; Healy NA; Hilsenbeck SG; Phillips GL; Chamness GC; Rimawi MF; Osborne CK; Schiff R
    Breast Cancer Res; 2011; 13(6):R121. PubMed ID: 22123186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.
    Groeneweg JW; Hernandez SF; Byron VF; DiGloria CM; Lopez H; Scialabba V; Kim M; Zhang L; Borger DR; Tambouret R; Foster R; Rueda BR; Growdon WB
    Clin Cancer Res; 2014 Dec; 20(24):6517-6528. PubMed ID: 25294905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
    Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
    Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.